At the heart of every therapeutic breakthrough are patients—and their loved ones—whose noble contributions to medical research pave the path to market for innovative treatments that improve outcomes and quality of life. In hematological malignancies—where global incidence is increasing and the median age for most diseases is 65-70 years of age—a patient-centered mindset is essential for addressing and overcoming barriers to clinical trial participation for this fragile patient population.
Increasingly, sponsors and regulators are emphasizing the importance of enhancing the patient experience in clinical trials to increase participation and generate meaningful data that truly reflects patients’ needs and preferences. When implemented successfully, patient-centric strategies promote higher engagement and, ultimately, improved healthcare outcomes.
In this webinar, you will learn:
- Drivers and benefits of patient centricity in the clinical trial landscape
- Why patient-centric approaches are important in populations with hematological malignancies
- Regulatory perspectives on the patient experience in clinical trials
- How to design and execute patient-centric hematological malignancy clinical trials, with real-life examples
Meet Our Speaker:
Ashley Herrick, Ph.D.
Executive Director, Oncology Program Strategy